Projectiles such as grass, dirt, and rocks caused 77% of injuries, and eye protection, including eyeglasses, was documented ...
The FDA has approved olanzapine extended-release injectable suspension (Weltruza; Teva Pharmaceuticals), a once-monthly ...
Kansteiner F. PhRMA launches new legal challenge as CMS brings 'most favored nation' pricing to Medicare Part B. Fierce ...
The number of people living with heart failure (HF) worldwide more than doubled between 1990 and 2023, reaching an estimated ...
Cost was cited at the top barrier to prescribing nonsteroidal mineralocorticoid antagonists (57%), sodium-glucose cotransporter 2 inhibitors (74%), and glucagon-like peptide 1 receptor agonists (84%).
Patients with early-onset, BRAF V600E–mutated metastatic colorectal cancer should receive combination therapy as soon as ...
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content ...
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps ...
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection. Invivyd plans to seek accelerated approval for VYD2311 based ...
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press. Insurance Business cited the AJMC study as evidence for its central argument: a larger PBM rebate ...
Esperion launched a nationwide awareness campaign for bumetanide nasal spray (Enbumyst), a short-term intranasal loop ...
A separate analysis of Aetna, Cigna, and UnitedHealthcare's 2025 TIC files, authored by Muhlestein and Yash Pathak and published in December 2025, found that physician and hospital outpatient data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results